The plasmin system in airway remodeling

Thrombosis Research

Volumn 112, Issue 1-2, 2003, Pages 1-7

  Kucharewicz, Iwona ^a   Kowal, Krzysztof ^a   Buczko, Wlodzimierz ^a   Bodzenta Łukaszyk, Anna ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Airway remodeling; Asthma; Plasmin system

Indexed keywords

BIOLOGICAL FACTOR; CYTOKINE; GROWTH FACTOR; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

AIRWAY; ASTHMA; CELL FUNCTION; GENE MAPPING; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT INFLAMMATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0842281342     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2003.10.011     Document Type: Review

References (87)

1. Vassalli J.D., Sappino A.P., Belin D. The plasminogen activator/plasmin system. J. Clin. Invest. 88:1991;1067-1072.
2. Kruithof E.K. Plasminogen activator inhibitors-a review. Enzyme. 40:1988;113-121.
3. Kruithof E.K., Vassalli J.D., Schleuning W.D., Mattaliano R.J., Bachmann F. Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937. J. Biol. Chem. 261:1986;11207-11213.
4. Levi M., Roem D., Kamp A.M., de Boer J.P., Hack C.E., ten Cate J.W. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo. Thromb. Haemost. 69:1993;141-146.
5. Cunnane G., FitzGerald O., Hummel K.M., Youssef P.P., Gay R.E., Gay S.et al. Synovial tissue protease gene expression and joint erosions in early rheumatoid arthritis. Arthritis Rheum. 44:2001;1744-1753.
6. Senior R.M., Tegner H., Kuhn C., Ohlsson K., Starcher B.C., Pierce J.A. The induction of pulmonary emphysema with human leukocyte elastase. Am. Rev. Respir. Dis. 116:1977;469-475.
7. Tarlton J.F., Whiting C.V., Tunmore D., Bregenholt S., Reimann J., Claesson M.H.et al. The role of up-regulated serine proteases and matrix metalloproteinases in the pathogenesis of a murine model of colitis. Am. J. Pathol. 157:2000;1927-1935.
8. Vos C.M., van Haastert E.S., de Groot C.J., van der Valk P., de Vries H.E. Matrix metalloproteinase-12 is expressed in phagocytotic macrophages in active multiple sclerosis lesions. J. Neuroimmunol. 138:2003;106-114.
9. Jacob M.P., Badier-Commander C., Fontaine V., Benazzoug Y., Feldman L., Michel J.B. Extracellular matrix remodeling in the vascular wall. Pathol. Biol. (Paris). 49:2001;326-332.
10. Khalil N., Corne S., Whitman C., Yacyshyn H. Plasmin regulates the activation of cell-associated latent TGF-beta 1 secreted by rat alveolar macrophages after in vivo bleomycin injury. Am. J. Respir. Cell. Mol. Biol. 15:1996;252-259.
11. Coughlin S.R. Thrombin signalling and protease-activated receptors. Nature. 407:2000;258-264.
12. Stewart G.A., Thompson P.J., Simpson R.J. Protease antigens from house dust mite. Lancet. 2:1989;154-155.
13. Portnoy J., Olson I., Pacheco F., Barnes C. Affinity purification of a major Alternaria allergen using a monoclonal antibody. Ann. Allergy. 65:1990;109-114.
14. Maruo K., Akaike T., Matsumura Y., Kohmoto S., Inada Y., Ono T.et al. Triggering of the vascular permeability reaction by activation of the Hageman factor-prekallikrein system by house dust mite proteinase. Biochim. Biophys. Acta. 1074:1991;62-68.
15. Nagata S., Glovsky M.M. Activation of human serum complement with allergens: I. Generation of C3a, C4a, and C5a and induction of human neutrophil aggregation. J. Allergy Clin. Immunol. 80:1987;24-32.
16. Chu C.T., Pizzo S.V. Receptor-mediated antigen delivery into macrophages. Complexing antigen to alpha 2-macroglobulin enhances presentation to T cells. J. Immunol. 150:1993;48-58.
17. Jeffery P.K., Godfrey R.W., Adelroth E., Nelson F., Rogers A., Johansson S.A. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. Am. Rev. Respir. Dis. 145:1992;890-899.
18. Johnson P.R.A., Black J.L., Tamm M. Proliferation of asthmatic and non asthmatic smooth muscle cells in culture-effect of formoterol and budesonide. Am. J. Respir. Crit. Care Med. 163:2001;A270.
19. Sillaber C., Baghestanian M., Bevec D., Willheim M., Agis H., Kapiotis S.et al. The mast cell as site of tissue-type plasminogen activator expression and fibrinolysis. J. Immunol. 162:1999;1032-1041.
20. van Hinsbergh V.W. Regulation of the synthesis and secretion of plasminogen activators by endothelial cells. Haemostasis. 18:1988;307-327.
21. Chapman H.A. Jr., Vavrin Z., Hibbs J.B. Jr. Macrophage fibrinolytic activity: identification of two pathways of plasmin formation by intact cells and of a plasminogen activator inhibitor. Cell. 28:1982;653-662.
22. Simpson A.J., Booth N.A., Moore N.R., Bennett B. Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J. Clin. Pathol. 44:1991;139-143.
23. Amin K., Ludviksdottir D., Janson C., Nettelbladt O., Bjornsson E., Roomans G.M.et al. Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma. BHR Group. Am. J. Respir. Crit. Care Med. 162:2000;2295-2301.
24. Gundersen D., Tran-Thang C., Sordat B., Mourali F., Ruegg C. Plasmin-induced proteolysis of tenascin-C: modulation by T lymphocyte-derived urokinase-type plasminogen activator and effect on T lymphocyte adhesion, activation, and cell clustering. J. Immunol. 158:1997;1051-1060.
25. Bianchi E., Ferrero E., Fazioli F., Mangili F., Wang J., Bender J.R.et al. Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes. J. Clin. Invest. 98:1996;1133-1141.
26. Cho S.H., Tam S.W., Demissie-Sanders S., Filler S.A., Oh C.K. Production of plasminogen activator inhibitor-1 by human mast cells and its possible role in asthma. J. Immunol. 165:2000;3154-3161.
27. Hart P.H., Vitti G.F., Burgess D.R., Singleton D.K., Hamilton J.A. Human monocytes can produce tissue-type plasminogen activator. J. Exp. Med. 169:1989;1509-1514.
28. Castellote J.C., Grau E., Linde M.A., Pujol-Moix N., Rutllant M.L. Detection of both type 1 and type 2 plasminogen activator inhibitors in human monocytes. Thromb. Haemost. 63:1990;67-71.
29. Fuchs-Buder T., de Moerloose P., Ricou B., Reber G., Vifian C., Nicod L.et al. Time course of procoagulant activity and D dimer in bronchoalveolar fluid of patients at risk for or with acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 153:1996;163-167.
30. Hummel S., Beck E., Brachmann I. D-dimer level in BAL and exhalation of patients with idiopathic pulmonary fibrosis (IPF), pulmonary sarcoidois and exogens allergic alveolitis (EAA). Am. J. Respir. Crit. Care Med. 153:1996;A315.
31. Samad F., Bergtrom G., Amrani D.L. Regulation of plasminogen activation by interleukin-6 in human lung fibroblasts. Biochim. Biophys. Acta. 1221:1994;307-314.
32. Hamilton J.A., Whitty G.A., Last K., Royston A.K., Hart P.H., Burgess D.R. Interleukin-4 suppresses plasminogen activator inhibitor-2 formation in stimulated human monocytes. Blood. 80:1992;121-125.
33. Gyetko M.R., Wilkinson C.C., Sitrin R.G. Monocyte urokinase expression: modulation by interleukins. J. Leukoc. Biol. 53:1993;598-601.
34. Gyetko M.R., Shollenberger S.B., Sitrin R.G. Urokinase expression in mononuclear phagocytes: cytokine-specific modulation by interferon-gamma and tumor necrosis factor-alpha. J. Leukoc. Biol. 51:1992;256-263.
35. Nykjaer A., Moller B., Todd R.F. 3rd, Christensen T., Andreasen P.A., Gliemann J.et al. Urokinase receptor. An activation antigen in human T lymphocytes. J. Immunol. 152:1994;505-516.
36. Waltz D.A., Sailor L.Z., Chapman H.A. Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors. J. Clin. Invest. 91:1993;1541-1552.
37. Hamilton J.A., Whitty G.A., Stanton H., Wojta J., Gallichio M., McGrath K.et al. Macrophage colony-stimulating factor and granulocyte-macrophage colony-stimulating factor stimulate the synthesis of plasminogen-activator inhibitors by human monocytes. Blood. 82:1993;3616-3621.
38. Stack M.S., Johnson D.A. Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). J. Biol. Chem. 269:1994;9416-9419.
39. Ryan T.J., Lai L., Malik A.B. Plasmin generation induces neutrophil aggregation: dependence on the catalytic and lysine binding sites. J. Cell. Physiol. 151:1992;255-261.
40. Shigeta O., Kojima H., Jikuya T., Terada Y., Atsumi N., Sakakibara Y.et al. Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass. Circulation. 96:1997;569-574.
41. Chang W.C., Shi G.Y., Chow Y.H., Chang L.C., Hau J.S., Lin M.T.et al. Human plasmin induces a receptor-mediated arachidonate release coupled with G proteins in endothelial cells. Am. J. Physiol. 264:1993;C271-281.
42. Weide I., Romisch J., Simmet T. Contact activation triggers stimulation of the monocyte 5-lipoxygenase pathway via plasmin. Blood. 83:1994;1941-1951.
43. Syrovets T., Jendrach M., Rohwedder A., Schule A., Simmet T. Plasmin-induced expression of cytokines and tissue factor in human monocytes involves AP-1 and IKKbeta-mediated NF-kappaB activation. Blood. 97:2001;3941-3950.
44. Deng G., Curriden S.A., Wang S., Rosenberg S., Loskutoff D.J. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell. Biol. 134:1996;1563-1571.
45. Stefansson S., Lawrence D.A. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature. 383:1996;441-443.
46. Wei Y., Lukashev M., Simon D.I., Bodary S.C., Rosenberg S., Doyle M.V.et al. Regulation of integrin function by the urokinase receptor. Science. 273:1996;1551-1555.
47. Rijneveld A.W., Levi M., Florquin S., Speelman P., Carmeliet P., van Der Poll T. Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J. Immunol. 168:2002;3507-3511.
48. Elias J.A., Zhu Z., Chupp G., Homer R.J. Airway remodeling in asthma. J. Clin. Invest. 104:1999;1001-1006.
49. Jeffery P.K. Remodeling in asthma and chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 164:2001;S28-38.
50. Busse W., Elias J., Sheppard D., Banks-Schlegel S. Airway remodeling and repair. Am. J. Respir. Crit. Care Med. 160:1999;1035-1042.
51. Laitinen L.A., Laitinen A., Haahtela T. Airway mucosal inflammation even in patients with newly diagnosed asthma. Am. Rev. Respir. Dis. 147:1993;697-704.
52. Jeffery P.K., Wardlaw A.J., Nelson F.C., Collins J.V., Kay A.B. Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivity. Am. Rev. Respir. Dis. 140:1989;1745-1753.
53. Chetta A., Foresi A., Del Donno M., Bertorelli G., Pesci A., Olivieri D. Airways remodeling is a distinctive feature of asthma and is related to severity of disease. Chest. 111:1997;852-857.
54. Vignola A.M., Riccobono L., Mirabella A., Profita M., Chanez P., Bellia V.et al. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am. J. Respir. Crit. Care Med. 158:1998;1945-1950.
55. Mautino G., Oliver N., Chanez P., Bousquet J., Capony F. Increased release of matrix metalloproteinase-9 in bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics. Am. J. Respir. Cell. Mol. Biol. 17:1997;583-591.
56. Matrisian L.M. The matrix-degrading metalloproteinases. Bioessays. 14:1992;455-463.
57. Okada Y., Naka K., Kawamura K., Matsumoto T., Nakanishi I., Fujimoto N. et al. Localization of matrix metalloproteinase 9 (92-kilodalton gelatinase/ type IV collagenase=gelatinase B) in osteoclasts: implications for bone resorption. Lab. Invest. 72:1995;311-322.
58. Oh C.K., Ariue B., Alban R.F., Shaw B., Cho S.H. PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model. Biochem. Biophys. Res. Commun. 294:2002;1155-1160.
59. Eitzman D.T., McCoy R.D., Zheng X., Fay W.P., Shen T., Ginsburg D.et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J. Clin. Invest. 97:1996;232-237.
60. Margaglione M., Cappucci G., d'Addedda M., Colaizzo D., Giuliani N., Vecchione G.et al. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. Arterioscler. Thromb. Vasc. Biol. 18:1998;562-567.
61. Xu J., Postma D.S., Howard T.D., Koppelman G.H., Zheng S.L., Stine O.C. et al. Major genes regulating total serum immunoglobulin E levels in families with asthma. Am. J. Hum. Genet. 67:2000;1163-1173.
62. Dawson S.J., Wiman B., Hamsten A., Green F., Humphries S., Henney A.M. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J. Biol. Chem. 268:1993;10739-10745.
63. Buckova D., Izakovicova Holla L., Vacha J. Polymorphism 4G/5G in the plasminogen activator inhibitor-1 (PAI-1) gene is associated with IgE-mediated allergic diseases and asthma in the Czech population. Allergy. 57:2002;446-448.
64. Cho S.H., Hall I.P., Wheatley A., Dewar J., Abraha D., Del Mundo J.et al. Possible role of the 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene in the development of asthma. J. Allergy. Clin. Immunol. 108:2001;212-214.
65. Wojta J., Kaun C., Zorn G., Ghannadan M., Hauswirth A.W., Sperr W.R.et al. C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. Blood. 100:2002;517-523.
66. Swaisgood C.M., French E.L., Noga C., Simon R.H., Ploplis V.A. The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system. Am. J. Pathol. 157:2000;177-187.
67. Sommerhoff C.P. Mast cell tryptases and airway remodeling. Am. J. Respir. Crit. Care Med. 164:2001;S52-58.
68. Thomas V.A., Wheeless C.J., Stack M.S., Johnson D.A. Human mast cell tryptase fibrinogenolysis: kinetics, anticoagulation mechanism, and cell adhesion disruption. Biochemistry. 37:1998;2291-2298.
69. Saksela O., Hovi T., Vaheri A. Urokinase-type plasminogen activator and its inhibitor secreted by cultured human monocyte-macrophages. J. Cell. Physiol. 122:1985;125-132.
70. Yu H., Maurer F., Medcalf R.L. Plasminogen activator inhibitor type 2: a regulator of monocyte proliferation and differentiation. Blood. 99:2002;2810-2818.
71. Kumar S., Baglioni C. Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2. J. Biol. Chem. 266:1991;20960-20964.
72. Dickinson J.L., Bates E.J., Ferrante A., Antalis T.M. Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function. J. Biol. Chem. 270:1995;27894-27904.
73. Shetty S., Idell S. Urokinase induces expression of its own receptor in Beas2B lung epithelial cells. J. Biol. Chem. 276:2001;24549-24556.
74. Montemurro P., Barbuti G., Conese M., Gabriele S., Petio M., Colucci M. et al. Retinoic acid stimulates plasminogen activator inhibitor 2 production by blood mononuclear cells and inhibits urokinase-induced extracellular proteolysis. Br. J. Haematol. 107:1999;294-299.
75. Ritchie H., Robbie L.A., Kinghorn S., Exley R., Booth N.A. Monocyte plasminogen activator inhibitor 2 (PAI-2) inhibits u-PA-mediated fibrin clot lysis and is cross-linked to fibrin. Thromb. Haemost. 81:1999;96-103.
76. Wilborn J., Bailie M., Coffey M., Burdick M., Strieter R., Peters-Golden M. Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J. Clin. Invest. 97:1996;1827-1836.
77. Kowal-Bielecka O., Distler O., Kowal K., Siergiejko Z., Chwiecko J., Sulik A.et al. Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma disease. Arthritis Rheum. 48:2003;1639-1646.
78. Henderson W.R. Jr., Lewis D.B., Albert R.K., Zhang Y., Lamm W.J., Chiang G.K.et al. The importance of leukotrienes in airway inflammation in a mouse model of asthma. J. Exp. Med. 184:1996;1483-1494.
79. Zeldin D.C. The 5-lipoxygenase pathway: a new therapeutic target for the treatment of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 165:2002;146-147.
80. Henderson W.R. Jr., Tang L.O., Chu S.J., Tsao S.M., Chiang G.K., Jones F.et al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am. J. Respir. Crit. Care Med. 165:2002;108-116.
81. Irvin C.G., Tu Y.P., Sheller J.R., Funk C.D. 5-Lipoxygenase products are necessary for ovalbumin-induced airway responsiveness in mice. Am. J. Physiol. 272:1997;L1053-1058.
82. Peters-Golden M., Bailie M., Marshall T., Wilke C., Phan S.H., Toews G.B.et al. Protection from pulmonary fibrosis in leukotriene-deficient mice. Am. J. Respir. Crit. Care Med. 165:2002;229-235.
83. Tanaka H., Masuda T., Tokuoka S., Komai M., Nagao K., Takahashi Y.et al. The effect of allergen-induced airway inflammation on airway remodeling in a murine model of allergic asthma. Inflamm. Res. 50:2001;616-624.
84. Levi-Schaffer F., Garbuzenko E., Rubin A., Reich R., Pickholz D., Gillery P.et al. Human eosinophils regulate human lung- and skin-derived fibroblast properties in vitro: a role for transforming growth factor beta (TGF-beta). Proc. Natl. Acad. Sci. U. S. A. 96:1999;9660-9665.
85. Minshall E.M., Leung D.Y., Martin R.J., Song Y.L., Cameron L., Ernst P. et al. Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. Am. J. Respir. Cell. Mol. Biol. 17:1997;326-333.
86. Khalil N., O'Connor R.N., Flanders K.C., Unruh H. TGF-beta 1, but not TGF-beta 2 or TGF-beta 3, is differentially present in epithelial cells of advanced pulmonary fibrosis: an immunohistochemical study. Am. J. Respir. Cell. Mol. Biol. 14:1996;131-138.
87. Zhang K., Flanders K.C., Phan S.H. Cellular localization of transforming growth factor-beta expression in bleomycin-induced pulmonary fibrosis. Am. J. Pathol. 147:1995;352-361.